Ariana Pelosci

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.

Sintilimab, both as a single agent and in combination with chemotherapy, generated comparable efficacy and safety vs pembrolizumab in patients with untreated metastatic non–small cell lung cancer.

Tucatinib plus first-line standard-of-care maintenance therapy with trastuzumab and pertuzumab is being investigated for its ability to improve progression-free survival and maintain health-related quality of life in patients with HER2-positive metastatic breast cancer.

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.

Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.

Ixazomib plus daratumumab without dexamethasone showed a positive efficacy profile for elderly frail patients with relapsed/refractory multiple myeloma, according to results of the phase 2 IFM 2018-02 study.

The use of 131-iodine generated high rates of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia who did not achieve a complete response following standard therapy.

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

The addition of adebrelimab to chemotherapy elicited improved overall survival compared with chemotherapy and placebo in patients with extensive-stage small cell lung cancer.

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

When maintenance niraparib was administered at an individualized starting dose, it resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, irrespective of biomarker status.

Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance.

Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone

The use of ctDNA assays may help identify patients with colorectal cancer who could benefit from adjuvant chemotherapy.

The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.

Ibrutinib-containing combinations demonstrated continued progression-free survival benefit compared with standard bendamustine plus rituximab in elderly patients with previously untreated chronic lymphocytic leukemia.

Cost and personal time spent on managing adverse effects for treatment with ibrutinib, acalabrutinib, or venetoclax could inform decision-making strategies for treatment selection in patients with chronic lymphocytic leukemia.

Daratumumab, lenalidomide, and dexamethasone demonstrated an overall survival advantage in the first-line setting compared with the same agents in the second-line setting in patients with transplant-ineligible multiple myeloma.

Metformin failed to improve invasive disease-free survival or overall survival when used as adjuvant treatment in patients with early breast cancer, irrespective of estrogen or progesterone receptor status.

Mobocertinib was found to provide a meaningful clinical benefit with acceptable tolerability in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer who had previously achieved disease control of 6 months or longer with EGFR TKIs.

Mobocertinib plus ado-trastuzumab emtansine demonstrated inhibitory effects in HER2 exon 20 insertion–mutated lung cancer cell lines.